Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ClinProt chosen for cancer biomarker discovery
June 2005
SHARING OPTIONS:

MELBOURNE, Australia At the Biomarker World Conference 2005 in Philadelphia, Melbourne-based HealthLinx Pty. Ltd., announced it has entered a collaboration with Bruker Daltonics Inc., a leading mass-spectrometry company. The collaboration focuses on technology transfer and cooperation between the two firms to develop disease-specific assays for use in in-vitro diagnostic (IVD) research and clinical trials using Bruker Daltonics' ClinProt platform technology for clinical proteomics.
 
The collaboration involves the on-going discovery of new biomarkers for predictive diagnostic applications using Bruker Daltonics' autoflex MALDI-TOF mass spectrometer in combination with proprietary ClinProt magnetic bead sample preparation, and ClinProTools software for advanced visualization and bioinformatics. Health-Linx will apply this technology platform to develop and commercialize biomarker applications in women's health for both research and clinical diagnostics. It is envisioned that, following validation, Australian government Therapeutic Goods Admin-istration (TGA) registration of the ClinProt platform as a diagnostic pathology device will be sought. TGA registration has effect in both Australia and New Zealand, and is valuable in Singapore and Europe.
 
Greg Rice of the Baker Heart Research Institute in Melbourne, and chief scientific officer of HealthLinx, stated: "The first IVD product to be developed under the collaboration will be an ovarian cancer test that will utilize four biomarkers found in the serum of women with ovarian cancer, building on HealthLinx's extensive experience and core competencies in ovarian cancer biomarker panel research."
 
HealthLinx Chief Executive Officer Nick Gatsios added: "At the same time, Health-Linx has contracted Walter Eliza Hall Institute of Medical Research (WEHI) in Melbourne to develop proprietary monoclonal antibodies, which are currently being cloned and purified, specific to its biomarkers. These will be used to build the next-generation product, for application on the Bruker Daltonics platform. FDA registration will be sought through industry partnerships for use as a pathology diagnostic."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.